Savina Pharma

Savina Pharma is a UK-based biotechnology company specializing in the discovery and development of small molecule therapeutics that target deubiquitinating enzymes (DUBs). The company utilizes its proprietary DUB Discovery Platform to identify highly selective inhibitors for targets like USP7, which are known to play pivotal roles in cancer progression and immune system regulation. By focusing on the ubiquitin-proteasome system, Savina aims to address unmet medical needs in oncology and immunology through the modulation of protein degradation pathways. The leadership team consists of experienced drug hunters with a history of successful biotech ventures. Currently, the company's programs are in the pre-clinical and discovery stages, with a focus on advancing lead candidates toward clinical trials.